|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Denosumab compared with zoledronic acid for the treatment of bone metastases in pa tients with advanced breast cancer: a randomized, double-blind study显示文摘 | Stopeck A T Lipton A Body J J | 2010 | J Clin Oncol2010，28，35： | 1 |
| 2 | Denosumab com- pared with zoledronic acid for the treatment of bone me- tastases in patients with advanced breast cancer: a ran- domized, double-blind study显示文摘 | Stopeck AT Lipton A Body J J | 2010 | J Clin Oneol2010，28，35： | 1 |
| 3 | Superiority of denosumab to zoledronic acid for prevention of skeletal-re- lated events: A combined analysis of 3 pivotal, ran- domised, phase 3 trials显示文摘 | Lipton A Fizazi K Stopeck AT | 2012 | Eur J Cancer2012，48，16： | 1 |
| 4 | Phase Ⅱ trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)显示文摘 | Modi S Sugarman S Stopeck A | 2008 | J ClinOncol2008，26，5： | 1 |
| 5 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study 显示文摘 | Stopeck AT Lipton A Body JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 6 | Combination of trastuzumab and tanespimycin (17-AAG,KOS -953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer:a phase Ⅰ dose-escalation study显示文摘 | Modi S Stopeck AT Gordon MS | 2007 | J Clin Oncol2007，25，： | 1 |
| 7 | Pain outcomes in patients with advanced breast cancer and bone metastases:results from a randomized,double-blind study of denosumab and zoledronic acid显示文摘 | Cleeland CS Body JJ Stopeck A | | 0，，04： | 1 |
| 8 | Phase Ⅰ trial of a novel epothilone,KOS-1584,using a weekly dosing schedule显示文摘 | Stopeck A Thomas E Jones S | 2006 | J Clin Oncol2006，24，： | 1 |
| 9 | Caring for the breast cancersurvivor:a guide for primary care physicians显示文摘 | Chalasani P Downey L Stopeck AT | 2010 | Am J Med2010，123，6： | 1 |
| 10 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,doubleblind study显示文摘 | STOPECK AT LIPTON A BODY JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 11 | Randomized, placebo- controlled, double-blind, phase Ⅱ study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer显示文摘 | Rugo HS Stopeck AT Joy AA | 2011 | J Clin Oncol2011，29，18： | 1 |
| 12 | Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA显示文摘 | Clark PR Stopeck AT Ferrari M | 2000 | Cancer Gene Therapy2000，7，6： | 1 |
| 13 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double- blind study显示文摘 | Stopeck AT Lipton A Body J J | 2010 | J Clin Oncol2010，28，35： | 1 |
| 14 | Phase Ⅱ study of SU5416,a small molecule vascular endo-thelial growth factor tyrosine kinase receptor inhibitor,in patients with refractory multiple myeloma显示文摘 | ZANGARI M ANAISSIE E STOPECK A | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 15 | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes显示文摘 | Giles FJ Stopeck AT Silverman LR | 2003 | Blood2003，102，3： | 1 |
| 16 | Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors显示文摘 | Alison Stopeck Ursa Brown-Glaberman | 2012 | Biologics: Targets and Therapy . 2012 (defa)2012，，： | 1 |
| 17 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized,double-blind study 显示文摘 | Stopeck AT Lipton A Body JJ | 2010 | J Clin Oncol2010，28，35： | 1 |
| 18 | Studies of direct intratum oral geng trsnsfor using cationic lipid-complexed plasmidDNA显示文摘 | Clark PR Stopeck AT Ferrari M | 2000 | Cancer Gene Ther2000，7，6： | 1 |
| 19 | A phase 2 trial of standard-dose eyelophosphamide, doxorubicin, vineristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515显示文摘 | Stopeck AT Unger JM Rimsza LM | 2012 | Blood2012，120，6： | 1 |
| 20 | HSP90 inhibition iseffective in breast cancer; a phase II trial of tanespimycin ( 17-AAG) plus trastuzumab in patients with HER2-positive metastaticbreast cancer progressing on trastuzumab 显示文摘 | MODI S STOPECK A LINDEN H | 2011 | Clin Cancer Res2011，17，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员